New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
10:47 EDTINCYIncyte announces results from RESPONSE trial evaluating ruxolitinib
Incyte announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera. Ruxolitinib, compared to best available therapy (BAT), significantly improved hematocrit control without the need for phlebotomy and reduced spleen size in patients with uncontrolled PV. Findings from the RESPONSE study are being presented in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology. At a median follow-up of 81 weeks, 85% of patients in the ruxolitinib arm were still receiving treatment. Because most patients in the BAT group crossed over to receive ruxolitinib therapy at week 32, adverse events were evaluated at this time when exposure between groups was similar. The most common non-hematologic adverse events of any grade in the ruxolitinib group compared to the BAT group were headache, diarrhea, fatigue and pruritus. The company said, “One out of four patients with polycythemia vera remain uncontrolled, face a profound symptom burden and are at greater risk of cardiovascular complications such as stroke and heart attack. These Phase III data give us confidence that ruxolitinib has the potential to become an important new treatment option for patients with uncontrolled PV who are no longer responding to or are intolerant of hydroxyurea.”
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 18, 2015
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.
August 17, 2015
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use